Increased risk of endometrial carcinoma among users of conjugated estrogens.
The possibility that the use of conjugated estrogens increases the risk of endometrial carcinoma was investigated in patients and a twofold age-matched control series from the same population. Conjugated estrogens (principally sodium estrone sulfate) use was recorded for 57 per cent of 94 patients with endometrial carcinoma, and for 15 per cent of controls. The corresponding point estimate of the (instantaneous) risk ratio was 7.6 with a one-sided 95 per cent lower confidence limit of 4.7. The risk-ratio estimate increased with duration of exposure: from 5.6 for 1 to 4.9 years exposure to 13.9 for seven or more years. The estimated proportion of cases related to conjugated estrogens, the etiologic fraction, was 50 per cent with a one-sided 95 per cent lower confidence limit of 41 per cent. These data suggest that conjugated estrogens have an etiologic role in endometrial carcinoma.
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000453:epidemiology; D002140:California; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects*; D004970:Estrone / Q000009:adverse effects; D005260:Female; D006801:Humans; D012306:Risk; D013997:Time Factors; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000453:epidemiology
D004966:Estrogens, Conjugated (USP); D004970:Estrone